Loading...
XJPX4547
Market cap1.06bUSD
Jan 17, Last price  
3,860.00JPY
1D
0.52%
1Q
0.26%
Jan 2017
32.51%
Name

Kissei Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XJPX:4547 chart
P/E
14.81
P/S
2.19
EPS
260.72
Div Yield, %
2.25%
Shrs. gr., 5y
-0.63%
Rev. gr., 5y
0.89%
Revenues
75.58b
+11.98%
60,938,000,00064,013,000,00064,179,000,00061,475,000,00064,538,000,00062,137,000,00064,387,000,00064,669,000,00062,494,000,00070,400,000,00070,108,000,00071,297,000,00071,707,000,00073,998,000,00072,302,000,00063,245,000,00069,044,000,00065,381,000,00067,493,000,00075,579,000,000
Net income
11.16b
+6.00%
4,734,000,0002,045,000,0001,571,000,0002,325,000,0002,061,000,0004,371,000,0004,004,000,0004,769,000,0005,019,000,0009,093,000,0007,165,000,0008,165,000,0007,726,000,0009,045,000,0005,481,000,0002,817,000,0005,285,000,00012,921,000,00010,528,000,00011,160,000,000
CFO
-1.68b
L-74.89%
4,563,000,0003,070,000,0003,958,000,0006,306,000,00011,579,000,00010,695,000,0004,688,000,0005,046,000,0009,287,000,00011,945,000,0006,667,000,0005,763,000,0006,441,000,0008,845,000,0006,346,000,00013,934,000,000-2,542,000,0001,533,000,000-6,679,000,000-1,677,000,000
Dividend
Mar 28, 20250 JPY/sh
Earnings
Jan 28, 2025

Profile

Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan.
URL
https://www.kissei.co.jp/
IPO date
Dec 22, 1988
Employees
1,359
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
75,579,000
11.98%
67,493,000
3.23%
65,381,000
-5.31%
Cost of revenue
47,712,000
45,509,000
44,506,000
Unusual Expense (Income)
NOPBT
27,867,000
21,984,000
20,875,000
NOPBT Margin
36.87%
32.57%
31.93%
Operating Taxes
3,159,000
3,046,000
3,475,000
Tax Rate
11.34%
13.86%
16.65%
NOPAT
24,708,000
18,938,000
17,400,000
Net income
11,160,000
6.00%
10,528,000
-18.52%
12,921,000
144.48%
Dividends
(3,722,000)
(3,135,000)
(2,536,000)
Dividend yield
2.33%
2.57%
2.15%
Proceeds from repurchase of equity
(6,000,000)
BB yield
3.75%
Debt
Debt current
1,340,000
1,490,000
1,640,000
Long-term debt
236,000
317,000
304,000
Deferred revenue
Other long-term liabilities
940,000
1,004,000
906,000
Net debt
(150,723,000)
(141,826,000)
(163,782,000)
Cash flow
Cash from operating activities
(1,677,000)
(6,679,000)
1,533,000
CAPEX
(1,201,000)
(2,547,000)
(1,919,000)
Cash from investing activities
8,690,000
6,001,000
10,776,000
Cash from financing activities
(10,006,000)
(3,420,000)
(2,756,000)
FCF
17,326,000
9,944,000
20,539,000
Balance
Cash
45,933,000
49,599,000
53,152,000
Long term investments
106,366,000
94,034,000
112,574,000
Excess cash
148,520,050
140,258,350
162,456,950
Stockholders' equity
210,117,000
344,745,000
344,717,000
Invested Capital
74,897,950
56,640,650
38,770,050
ROIC
37.57%
39.70%
49.16%
ROCE
11.39%
10.60%
9.60%
EV
Common stock shares outstanding
45,258
46,115
46,115
Price
3,535.00
33.85%
2,641.00
3.37%
2,555.00
4.29%
Market cap
159,988,218
31.36%
121,789,715
3.37%
117,823,825
3.05%
EV
10,372,218
142,124,715
108,689,825
EBITDA
32,121,000
26,093,000
24,605,000
EV/EBITDA
0.32
5.45
4.42
Interest
18,000
20,000
23,000
Interest/NOPBT
0.06%
0.09%
0.11%